New cancer vaccine Modi-1 enters human trials for four tumor types

NCT ID NCT05329532

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Scancell Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests a new vaccine called Modi-1, designed to train the immune system to attack cancer cells. It is given as a tiny shot into the skin using a special microneedle device. The trial includes 168 people with advanced triple-negative breast cancer, head and neck cancer, ovarian cancer, or kidney cancer. Some participants will receive the vaccine alone, and others will get it together with standard immune-boosting drugs like pembrolizumab or nivolumab. The main goals are to check safety and see if the vaccine triggers an immune response against the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Modi-1 moditope vaccine (given with a microneedle device, sometimes combined with pembrolizumab or nivolumab)
What this could lead to: If successful, this could point toward a new vaccine-based treatment that helps the immune system fight several types of advanced cancer.
What could go wrong: This is an early phase 1/2 trial, so safety and effectiveness are not yet proven. The vaccine may not work for all cancer types, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

childhood kidney cell carcinoma head and neck squamous cell carcinoma ovarian serous adenocarcinoma renal cell carcinoma Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA RENAL CELL CANCER SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Addenbrooke's Hospital, Cambridge University Hospitals
RECRUITING

Cambridge, United Kingdom

Contact Email: •••••@•••••
Belfast City Hospital
RECRUITING

Belfast, United Kingdom

Contact Email: •••••@•••••
Brighton and Sussex University Hospital
ACTIVE_NOT_RECRUITING

Brighton, Default, United Kingdom
Christie NHS Foundation Trust
RECRUITING

Manchester, Default, United Kingdom

Contact Email: •••••@•••••
Edinburgh Cancer Centre (NHS Lothian)
RECRUITING

Edinburgh, Default, United Kingdom

Contact Email: •••••@•••••
Imperial College Healthcare NHS Trust
ACTIVE_NOT_RECRUITING

London, Default, United Kingdom
Lancashire Teaching Hospitals NHS Foundation Trust
RECRUITING

Preston, Default, United Kingdom

Contact Email: •••••@•••••
Mount Vernon
RECRUITING

London, Default, United Kingdom

Contact Email: •••••@•••••
Nottingham University Hospitals Cancer Centre
RECRUITING

Nottingham, Default, United Kingdom

Contact Email: •••••@•••••
Royal Surrey NHS Foundation
RECRUITING

Guildford, Default, United Kingdom

Contact Email: •••••@•••••
Sheffield Teaching Hospital NHS Foundation Trust
RECRUITING

Sheffield, Default, United Kingdom

Contact Email: •••••@•••••
The Clatterbridge Cancer Centre NHS Foundation Trust
RECRUITING

Liverpool, CH63 4JY, United Kingdom

Contact Email: •••••@•••••
The Royal Marsden NHS Foundation Trust
NOT_YET_RECRUITING

Sutton, Default, United Kingdom

Contact Email: •••••@•••••
Torbay and South Devon NHS Foundation Trust
RECRUITING

Torquay, United Kingdom

Contact Email: •••••@•••••
University College London Hospital NHS Foundation Trust
RECRUITING

London, Default, United Kingdom

Contact Email: •••••@•••••
Velindre Cancer Centre
RECRUITING

Cardiff, Default, United Kingdom

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.